What's Happening?
Croma-Pharma has announced its strategic return to the orthopaedics market with the reacquisition of Synocrom™, a hyaluronic acid product used for treating knee osteoarthritis. This move marks a significant expansion of Croma-Pharma's portfolio, reconnecting
the company with its historical roots in orthopaedics. Synocrom™ was previously a leading hyaluronic acid brand in Europe, and its reintroduction is expected to build on Croma-Pharma's expertise in developing and manufacturing hyaluronic acid prefilled syringes. The product is MDR-certified, ensuring compliance with stringent EU regulatory requirements, and will be available to healthcare professionals in the EU and Switzerland starting May 2026.
Why It's Important?
The reacquisition of Synocrom™ by Croma-Pharma is important as it signifies the company's strategic expansion beyond its current focus on aesthetics into the orthopaedics market. This move not only broadens Croma-Pharma's product offerings but also reinforces its commitment to providing high-quality medical solutions. The availability of Synocrom™ in the EU and Switzerland will provide healthcare professionals with a reliable option for treating knee osteoarthritis, potentially improving patient outcomes. Additionally, this expansion could enhance Croma-Pharma's market position and drive growth by tapping into the demand for effective orthopaedic treatments.
